Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis. The biotechnology company said Monday that ...

Welcome, nurturing Cancer! You are celebrated for your deep empathy, intuitive nature, and fierce protectiveness of your loved ones. Cancer signs may seem prickly at first meeting, but once they ...

June 30 (Reuters) - Amgen (AMGN.O), opens new tab said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.